Bluebird bio completes spinout of oncology business 2seventy bio

Eleven months after announcing the split, bluebird bio Inc. has finished the separation of its cancer business. The oncology unit is now its own, publicly traded company, called 2seventy bio, named for what CEO Nick Leschly contends is "the maximum speed of human thought."